Jane Street’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.4M | Sell |
34,600
-14,000
| -29% | -$4.76M | ﹤0.01% | 2361 |
|
|
2025
Q4 | $19.3M | Sell |
48,600
-1,600
| -3% | -$708K | ﹤0.01% | 1653 |
|
|
2025
Q3 | $22.9M | Buy |
50,200
+24,100
| +92% | +$9.81M | ﹤0.01% | 1537 |
|
|
2025
Q2 | $8.51M | Sell |
26,100
-95,400
| -79% | -$26.4M | ﹤0.01% | 2333 |
|
|
2025
Q1 | $32.8M | Sell |
121,500
-48,700
| -29% | -$12.5M | 0.01% | 938 |
|
|
2024
Q4 | $40M | Sell |
170,200
-19,100
| -10% | -$5.02M | 0.01% | 814 |
|
|
2024
Q3 | $52.1M | Sell |
189,300
-160,600
| -46% | -$41.8M | 0.01% | 680 |
|
|
2024
Q2 | $85M | Buy |
349,900
+188,900
| +117% | +$29.8M | 0.02% | 456 |
|
|
2024
Q1 | $24.1M | Buy |
161,000
+113,900
| +242% | +$19M | 0.01% | 1054 |
|
|
2023
Q4 | $9.02M | Buy |
47,100
+8,000
| +20% | +$1.36M | ﹤0.01% | 2085 |
|
|
2023
Q3 | $6.92M | Buy |
39,100
+16,100
| +70% | +$3.07M | ﹤0.01% | 2196 |
|
|
2023
Q2 | $4.37M | Sell |
23,000
-14,900
| -39% | -$2.95M | ﹤0.01% | 2941 |
|
|
2023
Q1 | $7.59M | Sell |
37,900
-31,100
| -45% | -$6.54M | ﹤0.01% | 1925 |
|
|
2022
Q4 | $16.4M | Sell |
69,000
-700
| -1% | -$149K | 0.01% | 1153 |
|
|
2022
Q3 | $14M | Sell |
69,700
-143,500
| -67% | -$27.4M | 0.01% | 1377 |
|
|
2022
Q2 | $31.1M | Buy |
213,200
+82,100
| +63% | +$11.6M | 0.01% | 808 |
|
|
2022
Q1 | $21.4M | Buy |
131,100
+91,300
| +229% | +$13.9M | 0.01% | 1209 |
|
|
2021
Q4 | $6.75M | Sell |
39,800
-107,600
| -73% | -$20M | ﹤0.01% | 2400 |
|
|
2021
Q3 | $27.8M | Buy |
147,400
+19,700
| +15% | +$3.7M | 0.01% | 910 |
|
|
2021
Q2 | $21.6M | Buy |
127,700
+50,700
| +66% | +$7.43M | 0.01% | 1023 |
|
|
2021
Q1 | $10.9M | Buy |
77,000
+8,500
| +12% | +$1.28M | 0.01% | 1467 |
|
|
2020
Q4 | $8.9M | Sell |
68,500
-1,700
| -2% | -$227K | ﹤0.01% | 1513 |
|
|
2020
Q3 | $10.2M | Buy |
70,200
+39,500
| +129% | +$5.61M | 0.01% | 1197 |
|
|
2020
Q2 | $4.55M | Sell |
30,700
-61,300
| -67% | -$8.26M | ﹤0.01% | 1963 |
|
|
2020
Q1 | $10M | Buy |
92,000
+40,000
| +77% | +$4.62M | 0.01% | 771 |
|
|
2019
Q4 | $5.99M | Buy |
+52,000
| New | +$5.18M | 0.01% | 947 |
|
|
2019
Q2 | – | Sell |
-2,600
| Closed | -$243K | – | 5080 |
|
|
2019
Q1 | $243K | Sell |
2,600
-12,700
| -83% | -$1.06M | ﹤0.01% | 4471 |
|
|
2018
Q4 | $1.12M | Sell |
15,300
-28,400
| -65% | -$2.18M | ﹤0.01% | 2406 |
|
|
2018
Q3 | $3.83M | Buy |
+43,700
| New | +$4.4M | 0.01% | 1260 |
|
|
2018
Q2 | – | Sell |
-10,000
| Closed | -$1.19M | – | 4916 |
|
|
2018
Q1 | $1.19M | Buy |
10,000
+6,000
| +150% | +$774K | ﹤0.01% | 2437 |
|
|
2017
Q4 | $508K | Sell |
4,000
-92,500
| -96% | -$11.6M | ﹤0.01% | 3156 |
|
|
2017
Q3 | $11.3M | Buy |
96,500
+77,600
| +411% | +$6.62M | 0.04% | 470 |
|
|
2017
Q2 | $1.51M | Buy |
18,900
+7,600
| +67% | +$486K | 0.01% | 1765 |
|
|
2017
Q1 | $579K | Buy |
11,300
+5,000
| +79% | +$231K | ﹤0.01% | 2704 |
|
|
2016
Q4 | $236K | Buy |
+6,300
| New | +$264K | ﹤0.01% | 3589 |
|
|
2016
Q3 | – | Sell |
-8,800
| Closed | -$488K | – | 3951 |
|
|
2016
Q2 | $488K | Buy |
+8,800
| New | +$554K | ﹤0.01% | 2785 |
|
|
2015
Q4 | – | Sell |
-3,200
| Closed | -$257K | – | 3944 |
|
|
2015
Q3 | $257K | Buy |
3,200
+100
| +3% | +$11.1K | ﹤0.01% | 2941 |
|
|
2015
Q2 | $372K | Buy |
+3,100
| New | +$370K | ﹤0.01% | 2588 |
|
Other funds holding ALNY
VPM
VCM
Jane Street's ALNY Position: Q1 2026 in Review
Jane Street reduced its Alnylam Pharmaceuticals (ALNY) stake by 98% in Q1 2026, selling an estimated $104M and leaving 5,902 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #5136.
Jane Street first reported a position in ALNY in Q4 2013 and has held it in 43 quarters since. The position peaked at $437M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Jane Street held 5,902 shares of Alnylam Pharmaceuticals worth $1.95M as of Q1 2026.
- Jane Street sold 305,386 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $104M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5136 holding.
- Jane Street first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 43 quarters since.
- Jane Street's Alnylam Pharmaceuticals position peaked at $437M in Q3 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.